Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. 

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA

    usa-flagGenprice Inc, Logistics
    547, Yurok Circle
    San Jose, CA 95123
    Phone/Fax: 

    (408) 780-0908 

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    skype chat

    GENPRICE Inc. invoicing/ accounting:
    6017 Snell Ave, Suite 357
    San Jose, CA. 96123

     

    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Wednesday, 15 May 2013 12:07

    NATtrol CT.NG External Run Controls

    PRODUCT DESCRIPTION:
    NATtrol™ CT.NG External Run Controls (NATCT (434)-6MC, NATNG-6MC and NATCT.NGNEG-6MC) are formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. Each control pack contains 6 x 1.0 mL vials of C.trachomatis NATtrolTM, N.gonorrhoeae NATtrolTM or CT.NG Negative NATtrolTM. These controls are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

    INTENDED USE:
    - NATtrol™ CT.NG External Run Controls are full process controls designed to evaluate the performance of nucleic acid tests for determination of the presence of CT.NG DNA. NATCT(434)-6MC, NATNG-6MC and NATCT.NGNEG-6MC can also be used for quality control of clinical assays and training of laboratory personnel.
    - NATCT(434)-6MC, NATNG-6MC and NATCT.NGNEG-6MC contain intact organisms and should be run in a manner identical to that used for clinical specimens.

    ETIOLOGIC STATUS/BIOHAZARD TESTING:
    - NATtrol™ inactivation was carried out on each control. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
    - The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

    Catalog #:NATNG-6MC
    Catalog #:NATCT(434)-6MC
    Catalog #:NATCT.NGNEG-6MC

    For more information download PDF file

    Published in Promos
    Wednesday, 15 May 2013 11:16

    NATtrol BC.GP Panel

    PRODUCT DESCRIPTION:
    NATtrol™ BC.GP Panel (NATBC.GP-NNS) is formulated with purified, intact bacterial particles that have been chemically modified to render them non-infectious and refrigerator stable*. NATBC.GP-NNS contains 11 x 0.75 mL vials of bacterial NATtrol™ targets listed in Table 1. These panels are supplied in a purified protein matrix that mimics the composition of a true clinical specimen. *NATtrol™ Patents Pending

    INTENDED USE:
    - NATtrol™ BC.GP Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of bacterial nucleic acids. NATBC.GP-NNS can also be used for verification of clinical assays, development of diagnostic tests and training of laboratory personnel.
    - NATBC.GP-NNS contains intact organisms and should be run in a manner identical to that used for clinical specimens.

    ETIOLOGIC STATUS/BIOHAZARD TESTING:
    - NATtrol™ inactivation was carried out on the bacterial stock used to formulate panel members. The inactivation was verified by the absence of bacterial growth in a validated growth protocol.
    - The purified protein matrix was manufactured from materials that were screened and found to be negative for HIV 1&2 Ab, HBsAg, HTLV I&II Ab, HCV Ab, HIV RNA, HBV DNA and HCV RNA using FDA cleared kits at the single donor level.

    PRECAUTIONS:
    - Although NATBC.GP-NNS contains inactivated organisms, it should be handled as if potentially infectious.
    - Use Universal Precautions when handling this product.
    - To avoid cross-contamination, use separate pipette tips for all reagents.

    Catalog #: NATBC.GP-NNS 

    For more information donwload PDF file

    Published in Promos
    Monday, 29 April 2013 10:11

    Candida albicans Z006, DNA (1 μg)

    PRODUCT DESCRIPTION: Each aliquot contains 1 μg of DNA extracted from a pure culture of Candida albicans. The identification of this organism was confirmed by rDNA sequencing. The purity of the culture was monitored by additional culturing and Gram staining to detect any contaminating bacteria. The DNA was extracted from the cells following a protocol based on the yeast protocol provided in the Qiagen® Genomic DNA Handbook and using Qiagen® Genomic DNA Buffers with a 500/G genomic tip. DNA concentration and OD260/280 ratios are determined using a NanoDrop ND- 1000®. The extracted DNA also tested positive on an in-house real time PCR assay.

    INTENDED USE: Purified Genomic DNA is designed for use as an amplification and/or detection control for nucleic acid testing of Candida albicans. It can also be used to determine a limit of detection (LOD), in diagnostic assay development, cross-reactivity studies or genomic sequencing. When used as a control for nucleic acid tests, the same protocols as those used to amplify extracted clinical specimens should be employed.

    PRECAUTIONS:
    - Use Universal Precautions when handling Genomic DNA.
    - The material may be re-frozen after thawing. Repetitive freezing and thawing is not recommended (aliquot material if necessary).
    - To avoid cross-contamination, use separate pipette tips for all reagents.

    RECOMMENDED STORAGE:
    This control is supplied in TE Buffer and should be frozen at -20°C or below.

    DO NOT USE IN HUMANS:
    These products are intended for research, product development, quality assurance or manufacturing use. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

    Catalog #: 0801504DNA-1μg

    Contact us for additional information

     

    Published in Promos
    Friday, 19 April 2013 10:28

    The Human Papillomavirus

    The 3D model of HPVPapillomaviruses are a very diverse group of viruses that infect human skin and mucosal cells, which serve as a barrier between the environment and a human being. Most representatives of this group do not cause any symptoms, but highly pathogenic types may cause cancer. Ancient literature contains the first known mention of skin warts. The first classification of warts was introduced by Roman physician Aulus Cornelius Celsus in 25 AD, and the assumption that warts may be transmitted via infection originated even earlier. However, the viral nature of papillomas was not demonstrated until the beginning of the twentieth century (reviewed in 4). The first papillomavirus was isolated in 1933 by the American virologist Richard Shope, who also isolated an influenza virus.

    The evolutionary history of papillomaviruses seems to coincide with the origin of higher-order vertebrates, amniotes (including reptiles, birds, and mammals). Mammalian skin structure appears to make them the most suitable hosts for the papillomaviruses, and — today — papillomaviruses are widespread in mammals and rarely found in birds. The relationship between papillomaviruses and similar groups of DNA-viruses, such as polyomaviruses, is not well-demonstrated at the present time. There are more than a hundred types of papillomaviruseshigh-risk that can infect humans. These are collectively referred to as human papilloma viruses or HPV and are divided into (HR) and low-risk (LR) types by their carcinogenic properties. HPV are transmitted through direct skin-to-skin contact, and approximately 30 types are transmitted sexually. LR HPV are much more common than HR HPV among humans and often do not cause any symptoms. In fact, only 18 types of HPV pose a cancer risk, mostly for anogenital cancers.

    Current research suggests that LR HPVs produce more virions and infect more human hosts whereas HR types are less virulent but more difficult for the immune system to neutralize. The most dangerous HR HPV types are also the most widespread, HPV16 (reference strain) and HPV18, and the main cause of skin warts (especially in the anogenital zone) are HPV types 6 and 11. These and several other types of HPV attract serious attention.

    Human papilloma virus particles lack a lipid envelope and are relatively small, with a diameter of only about 30 nm. In comparison, the human immunodeficiency virus (HIV) and influenza virus virions are enveloped by a lipid bilayer derived from the host cell and are approximately four times larger. The papillomavirus genome consists of double-stranded DNA decorated and packed by histones of the host cell. It encodes two types of proteins, early (E) proteins and late (L) proteins: early HPV proteins maintain regulatory functions (and are responsible for oncotransformation of the host cell in the case of HR types), and late proteins form the capsid of the virion. The life cycle of HPV is bound to the life cycle of its host cells, keratinocytes, and HPV can only be cultivated in special organotypic raft cultures containing a population of cells at different developmental stages — similar to the skin of a living organism. Keratinocytes are the main cells of epidermis, the outermost layer of the skin. Actively dividing young keratinocytes are found near the basal membrane that separates the epidermis from other layers of the skin and move towards the skin surface during maturation. Viral particles infect non-differentiated cells, and new virions are produced inside the keratinocytes during the terminal stage of differentiation.

    The HPV early proteins are responsible for maintaining a proper amount of viral DNA inside the host cell nucleus. However, they also coordinate the expression of viral genes. Proteins E1 and E2 form a complex with viral DNA, which recruits the cell replication systems. Proteins E6 and E7 are responsible for the carcinogenic effect in HR HPV types. E6 is able to bind to the tumor suppressor p53 and promote its ubiquitination and degradation. Protein E7 binds several cell proteins and tumor suppressors, including theretinoblastoma protein. The activity of the E6 and E7 proteins leads to uncontrolled cell division.

    Late proteins of HPV form the viral capsid and mediate packaging of DNA into the virion. The pentamer-forming L1 protein is the major component of the HPV capsid, and the L2 protein is a minor constituent. The HPV capsid looks roughly spherical, but, in fact, it has a icosahedral symmetry with the triangulation number that equals 7. Rather than a structure based on pentamers mixed with hexamers (like that of the soccer ball), the HPV capsid is composed of 72 L1 pentamers of two different types — 60 hexavalent pentamers and 12 pentavalent pentamers (reviewed in 2, chapter 3). Remarkably, the fold of HPV L1 proteins is similar to that of human nucleoplasmins, the proteins that regulate the assembly of nucleosomes. Whether they share a common ancestor or whether their similarity is the result of convergent evolution is not yet clear. Perhaps the interaction between L1 and nucleosomes on viral DNA is crucial for the encapsidation of the HPV genetic material.

    One monomer of L2 is associated with each L1 pentamer of the HPV virion, and current research suggests that L2 is crucial for DNA recruitment to the viral particle. Some hypothesize that L2 — as well as L1 — may interact not with viral DNA but rather with its histones. To date, however, much of the process through which HPV DNA is packed inside the virion remains unknown. One facet of the process that is known may make HPV an important tool in human gene therapy: any segment of DNA less than 8 kb long may be packed inside the capsid [link], which enables the development and use of HPV-based transformation vectors. Interestingly, human cyclophilin participates in HPV capsid unpacking, a mechanism that has also been demonstrated for HIV.

    A growing interest in HPV research can be partially — if not wholly — attributed to discovery of the relationship between HPV and cancer and the subsequent Nobel Prize in Physiology or Medicine (2008) awarded for this work. German scientist Harald zur Hausen has shown that nearly all cases of cervical cancer are the result of HPV infection. Vaccines against HPV are currently being actively developed and introduced, and the main targets for such vaccines include the most dangerous and common HPV types: HPV6, HPV11, HPV16, HPV18.

    Dr. Christopher Buck from the U.S. National Cancer Institute: Current vaccines against human papillomaviruses (HPVs) are a triumph of applied structural virology. However, the current vaccines, which use recombinant virus-like particles composed of the L1 major capsid protein, do not protect against all disease-causing HPV types. Fortunately, a new generation of HPV vaccines targeting conserved „Achilles’ heel“ epitopes present in the L2 minor capsid protein promise to offer broad protection against all HPVs, including all types that cause cancer, as well as types that cause benign skin warts (for which the papillomavirus family is named). Current knowledge about the structure, dynamics, and function of L2 during the infectious entry process is very limited. This structural information is desperately needed to inform the development of pan-protective HPV vaccines.

    Published in News

    dna structure gentaurDNA is known to scientists for more than one hundred years. Swiss biologist Friedrich Miescher and chemist (doctor of education) identify it first in 1868 in the blood-soaked bandages and swabs of bandages for wounded soldiers in Tübingen, and later, after 1870 in Basel - the sperm of salmon of which the first isolate pure DNA. He called the discovery of the substance nuklein and in 1874 managed to break nucleic of protein and acid acid in 1889 was named by his student Richard Altman "nucleic". DNA is recognized as the only carrier of heredity in 1944 as a result of an experiment made ​​by Oswald Avery and his colleagues Colin McCarthy MakLoyd and MacLynn. The structure of the DNA double helix was discovered in 1953 by James Watson and Francis Crick at Cambridge University. For this discovery they received the Nobel Prize in Physiology or Medicine with Maurice Wilkins in whose lab made ​​X-ray crystallographic analysis of DNA, suggested to Watson and Crick's idea of ​​its structure.

     

    Published in News

    rna-dna-monoclonal-cytokes-anti-mouse-rat-knockViruses are not cells and cell structure, unlike bacteria, parasites, people and anything that is sure to take live. Note that life is first and viruses - the other. In fact, the majority of scientists consider viruses as a matter of the boundary between the living and the undead.

    How is this possible? Is not that a mistake?
     
    As is well known, living matter has the following immutable characteristics - ability to self-organize and self-reproduction. For this purpose, each living cell and in every living organism vital processes occur - feeding, respiration, excretion, etc., so to speak, keep cells and organisms alive. In viruses, however, things are very different.

    Generally, viruses are particles (but not cells!), Representing a small amount of DNA or RNA wrapped in a protein, fewer carbohydrates and / or lipids (fatty substances). Proteins on the surface of the viral envelope, which can have various forms, recognize and provide host cell of virus in it. When the virus enters the cell, its DNA is integrated in this cell that it "forces" to form virus particles assemble spontaneously and leave the cell.

    Viral just like living organisms, there are self-organization processes and reproduction. They, however, they are performed only in the host cell, and all other vital processes are absent altogether. By entering into the cell, viruses (which, incidentally, outside the cell are called virions) are completely dead particles. Only when entering it, they show some properties of living matter - samoorganizarane and reproduction. However, these qualities are not considered sufficient virus to be identified as living matter. For life is inherently inherent nutrition, respiration, excretion, etc. or summary speaking to a constant metabolism. Indeed, some organisms may greatly slow it down, but no body can stop it completely, and so called life.

    Viruses do not have their own structures to carry out metabolism, and harness resources and structures of the host cell to carry out its goals. Therefore, they can not be called living. Apparently, however, they are not dead matter, since if it gets into the cell organization and show a high capacity for self-reproduction - something completely alien to the undead.
     
    An interesting question is how the virus originated. It is believed that early in the evolution of the first primitive cells, viruses were parts of cells that are separate and distinct self-replicating particles. This theory is supported by the astonishing ease with which viruses penetrate into the cell and then subject yourself - it is placed entirely at their disposal, accepting them as part of ourselves.

    Published in News

    child with milk teethInterview with Dr. Alexiev Venelin.

    Since when there is a procedure to remove teeth to derive stem cells?

    In 2003, American scientists discovered that the pulp of milk teeth is a valuable source of biological mesenchymal stem cells that can be isolated and used cryopreservatеа treatment at a critical moment for the man. Scientific achievement is enormous. It's most popular method of extracting stem cells from the umbilical cord and placenta, add another one to the undeniable advantages. It gives parents a second chance, missed the first - to preserve stem cells at birth of their children. Today technology is successfully practiced in the U.S., UK, Greece and Bulgaria in two years.

    How and what are the indications for extraction of milk teeth?

    Milk tooth extraction is a safe, natural and completely noninvasive method for the extraction and storage of stem cells. Appropriate age from 5 to 12 years. For starters dentist tooth determine whether appropriate, inspection of front upper and lower teeth. Required tooth is with mild shaking.

    It is the root to be fully preserved tooth so not only leaves fall and be removed as soon as it starts to shake. Before the operation is done or sectoral panoramic photograph to determine the condition of the tooth and its removal is performed under local anesthesia.
    Remove the tooth is placed into a special set of transportation and transported quickly to the laboratory. The Bank tooth is examined to extract stem cells are stored at -196 C ˚. The entire process is accompanied by protocols to ensure the unique genetic material. Finally, the child's parents receive a certificate for successfully storing an initial period of 20 years.

    Experts recommend extraction of two teeth, because the pulp of a tooth leads to storage of biological material a sample application. Medical logic leads to the more material you have, the more therapeutic applications are given.

    Which of milk tooth are stem cells?

    In milk tooth pulp in the accumulation of dentin formed hermetically sealed and sterile space, which contains multiple stem cells. The pulp of the tooth is formed even in the embryonic stage of development of the organism and therefore the cells are young and are carriers of the original DNA. It has been shown that the pulp of a tooth contains from 1000 to 100 thousand units stem cells that can be isolated to reproduce by cell cultures to be implanted in the area of ​​the lesion, giving rise to a new tissue.

    What is the application?

    Stem cells from milk tooth is defined as mesenchymal, which have the ability to differentiate into tissue-forming cells - heart muscle, kidney, liver, muscle, tendons, cartilage, have the ability to form dentin. Currently, the treatment of diseases through tissue regeneration by mesenchymal stem cells is the most recent and rapidly developing trend in modern medicine.

    Research into stem cell therapy is rapidly evolving and offer hope for the treatment of juvenile diabetes, heart disease, arthritic disease, Parkinson's disease, Alzheimer's, spinal cord injury, multiple sclerosis and others. Japanese scientists have managed to create even new teeth in mice. All this is due to the ability of stem cells to differentiate into other cell types. Stem cells are the first motto of cells formed after fertilization, as these are the foundation of the dental pulp: mesenchymal, chondrocytes, osteoblasts and adipocytes.

    The fact is that stem cells isolated from cord blood and placenta are much stronger and more numerous than any other. Since there are immunologically mature, they are able to transform into different types of blood cells, making a real alternative for the treatment of 80 types of diseases, including leukemia, disease and Hodgkin lymphoma, breast cancer and testicular multiple sclerosis , a number of neurological diseases and others.

    Compared to undifferentiated cells derived from other tissue stem contained in the pulp of milk teeth, however, are very valuable because they reproduce faster, easier to differentiate into other cell types and can be extracted in many wider time range. But with aging stem cells slow their recovery and become much more efficient.

    Therefore scientific theory is that the earlier draw, the more effective they will be in time.

    Published in News

    On Friday at a National Geographic-sponsored TEDx conference, scientists met in Washington, D.C. to discuss which animals we should bring back from extinction. They also discussed the how, why, and ethics of doing so. They called it "de-extinction."

    There are a few guidelines for which ancient species are considered, and sadly, dinosaurs are so long dead they aren't in the picture. Their DNA has long ago degraded, so researchers are fairly sure that Jurassic Park will never happen.

    They chose the animals using the following criteria: Are the species desirable — do they hold an important ecological function or are they beloved by humans? Are the species practical choices — do we have access to tissue that could give us good quality DNA samples or germ cells to reproduce the species? And are they able to be reintroduced to the wild — are the habitats in which they live available and do we know why they went extinct in the first place?

    This still leaves plenty of other animals on the table. The list of candidates is actually pretty long, considering. The cost of de-extinction varies by species but projects could run into the hundreds of thousands of dollars, if not more. Then there's also the cost of housing the animals once they are created, and re-introducing them into the wild and protecting them from poachers once they are there.

    But, if you were the zoo that had that one Woolly mammoth or saber-toothed cat, these costs just might be worth it.

    Here are 10 animals they are hoping to one day resurrect.

     

    AurochsDodo Labrador Duck
    WoodpeckerWoolly MammothMastodon 
    QuaggaSaber toothedcatTasmanian Tiger
    Caribbean monk seal
    Published in News

     

    ExiProgen™ is a breakthrough in synthetic biology allowing for the synthesis and purification of one to 16 proteins per run. 
    DNA, in the form of plasmid or linear PCR product, is added to the system and Gentaur’s coupled transcription/translation E. coli extract then synthesizes the protein. 
    The crude protein extract is further purified, using His-Tag engineered into the proteins. 
    The net result is up to 100 ug of >90% pure Protein in about 6 hours. 
    ExiProgen™ can also purify Nucleic Acids from several sources, making it one of the most versatile systems available.

    Features and Benefits
    Built in protocols optimized for protein synthesis/purification and the extraction of a wide variety of nucleic acid samples
    ExiProgen™ has more contains over 900 protocols, each optimized for protein synthesis/purification and target nucleic acid type and source sample. This optimization enables the user to obtain reproducible results for every run, every day. The instrument software can also be upgraded through the network connection port so you can stay up-to-date with the best performing protocols
    Cooling Block
    ExiProgen™ has a built-in cooling block where the elution tube rack sits.
    Sample integrity is ensured by keeping the samples below 10°C.
    This allows for overnight runs and provides you with confidence in your results.
    Magnetic block & Heating block
    To increase extraction efficiency, the ExiProgen™ has an integrated combined magnetic/heating block. The combination of bead magnetization and sample heating reduces experiment time and increases elution efficiency, resulting in increased sample yield. The heating block’s precision temperature control also ensures reproducible results for protein synthesis reactions.
    Contamination Shield
    ExiProgen™ comes with a contamination shield designed to protect the assay from cross-contamination during instrument operation. Any time the pipette tips are moving, the contamination shield will slide under the tips, therefore eliminating the possibility of intra-assay cross-contamination which is a must when working with multiple samples.

    Easy to use LCD Touch screen
    The 3.5" touchscreen maximizes efficiency by offering an intuitive interface with simple push-button operation for processes such as selecting protocols and controlling the UV sterilization lamp.

    ExiProgen f04
    UV lamp
    ExiProgen™ has a powerful UV sterilization lamp that enables the user to sterilize the instrument chamber before and/or after every nucleic acid extraction or protein purification run. This prevents possible inter-assay cross-contamination that may occur on a busy work day.

    Experimental Procedure

    ExiProgen f05

     

    Principle of protein synthesis and purification
    ExiProgen™ Protein Synthesis Kit useds a E. coli extract to effect coupled transcription/translation of input DNA, which can be plasmid, or PCR generated DNA. The protein itself is generated with a His-Tag, which is then purified using the Ni-NTA magnetic bead provided. The result is high yields of protein that is >90% pure.

    ExiProgen f05 01

    Nucleic acid extraction principle
    ExiProgen™ DNA/ RNA Kits work on the principle of cell lysis, followed by bind, wash elute from silica magnetic beads. High yields of ultrapure DNA or RNA are obtained with OD260 readings of > 1.8 for DNA and 2.0 for RNA.

    ExiProgen f05 02

    And believe it or not it costs ONLY 15700 € !!!

    Order Button1

    Published in Top Products
    Tuesday, 19 March 2013 17:14

    Genetically modified foods? Do not panic!

    genetically-modified-foodsGenetically modified organisms can be defined as organisms in which the genetic material (DNA) has been altered intentionally. Technology by which this is achieved is often called recombinant DNA technology, recombinant technology or genetic engineering. This technology allows the transfer of genes from one organism to another, often unrelated - such as insulin and human growth hormone are produced in industrial quantities of yeast - single-celled fungi, which incidentally, is also used in the manufacture of wine, beer, bread, etc. .

    Recombinant technology becomes more pervasive in the plant, and hence in refrigerators in each of us. This creates many, absolutely unjustified panic and even hysteria in the community, professionals need to dispel. On the subject, however, to speak and many pseudo experts that only fueled false rumors and myths and incite panic extra.
     
    Topic is too broad, so here we only briefly describe the most relevant aspects.

    First we point out that genetically modified foods are not mass produced because scientists or even farmers love to experiment with crops, but because they have serious economic benefits. This most often increased resistance to pests, increase yields, reduced need for irrigation and / or fertilization compared to current varieties, or some combination of these qualities. Simply put, the plants are imported genes that give them resistance to pests, herbicides, drought etc.. This increases yields significantly reduces the cost of farmers. In fact, the root cause for the introduction of recombinant technology in plants is notably increasing their resistance to parasites and viral diseases.

    Many "experts" speak, often in the media, totally unprepared and totally unaware of the nature of the issue, as repeating ridiculous slogans such as "No mutants in the soup."
     
    What many do not realize is that every plant food, used by XIX century, is genetically modified. Plum, for example, is a type that does not exist in nature - it is created by crossing the wild plums and sloes. Melons are types created by polyploidization (technique in biotechnology that will clarify this). The wheat we eat every day in the form of daily bread is not created by nature and man the crossing of wild species.

    Many people seem to be afraid of the sound of the word mutant, but it's nothing terrible. It comes from the Latin mutatio, monstrosity does not mean, as many people probably think and change. Mutant mean modified organism, not a freak. In this sense, genetic engineering changes the plants (including those used for food) to make them better - more productive, more stable, etc. Without realizing it, people are engaged in genetic engineering since the dawn of civilization - and cross picking out certain individuals, they received new breeds and varieties in which a certain quality is selectively enhanced - production at chicken or the department of dairy cows crop yield etc. It is to the latter, for example, was established wheat, which is obtained by complex crosses of several plant species. Thus, the person creates something that nature could not create. In essence, the process of creating new plants through cross from the growers do not differ in anything from the analogous process in the laboratory. Nobody refuses melons, watermelons, bread and plum because not exist in nature and man-made "mutants". Why not give the new "genetically modified" foods? In the laboratory, scientists months can achieve results that would have taken decades of growers to be reached. Recombinant technologies also provide a number of completely new features that are unavailable through classical breeding and selection of animals or plants.

    For those who are still concerned about the presence of "mutants" on the shelves of supermarkets will clarify that food produced by biotechnology, pass more rigorous tests created a "traditional" - by crossing plants, selecting at high yield, etc. This is not the most appropriate solution because the two slightly different techniques and is much more likely with "traditional" method to create dangerous foods to be noticed than those to be created by means of biotechnological and reach supermarkets. Also, any kind of new biotech pass rigorous tests for toxicity, allergenicity, nutritional changes due to mutation, unforeseen health effects due to mutation and others.

    Some will point out this time somewhat appropriate that they can be obtained changes that make some people allergic to one food or another. It really is. But not all the new foods are tested for allergenicity? He is allergic to them, just not to consume them as people who are allergic to strawberries, do not eat them. The fact that some people are allergic to strawberries does not mean that strawberries should be banned for everyone. The same goes for GM foods.

    Published in News
    Page 3 of 4